Related references
Note: Only part of the references are listed.Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
Ralf-Dieter Hofheinz et al.
CLINICAL CANCER RESEARCH (2010)
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2010)
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy Results from an Open-Label, Randomized Phase II Clinical Trial
Martin Sebastian et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
Douglas W. McMillin et al.
NATURE MEDICINE (2010)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma
Bart Burington et al.
CLINICAL CANCER RESEARCH (2008)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
Klaus Mross et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Regulation of gene expression and cell division by Polo-like kinases
Szu Shien Ng et al.
CURRENT GENETICS (2006)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
Normal cells, but not cancer cells, survive severe Plk1 depletion
XQ Liu et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer
Yoshiaki Yamamoto et al.
ONCOLOGY (2006)
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma
M Mattioli et al.
ONCOGENE (2005)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
B Barlogie et al.
BLOOD (2001)